Friday, July 10, 2026

pharma · Myelofibrosis · Myelodysplastic syndromes (MDS)

Geron Netherlands

Geron Netherlands clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

EU HQ
EMA registrant Type
Company details
Status
Public
HQ
EU
Programs
3
Drugs
2
Patents
0
Intelligence · Clinical Programs

Geron Netherlands projects

3 ClinicalTrials.gov programs sponsored by Geron Netherlands.

Geron Netherlands has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 63935937MDS3001

    Geron Netherlands B.V.

    Myelodysplastic syndromes (MDS)

    phase 3 small molecule active

    1 trial
  2. GRN163LMYF3001

    Geron Netherlands B.V.

    Myelofibrosis

    phase 3 small molecule active

    1 trial
  3. Imetelstat

    Geron Netherlands B.V.

    Myelofibrosis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Geron Netherlands have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.